A. Primary Types of Pain
- Nociceptive Pain
- Heat and cold
- Acute intense mechanical force: surgery, trauma
- Chemical irritants
- Inflammatory Pain
- Direct tissue damage including neurons
- Mediated by various chemokines and cytokines
- Neuropathic Pain
- Peripheral nerve lesions - AIDS, diabetes mellitus, trauma recovery
- Central nervous system lesions - multiple sclerosis, spinal cord injury, stroke
- Functional Pain
- No clear lesions along pain tracks
- Due to abnormal responsiveness or function of nervous system
- Includes fibromyalgia, irritable bowel syndrome, some types of non-cardiac chest pain
- Mixed Types of Pain
- Cancer Pain
- Visceral Pain
B. Pain Sensation [1,2]
- Mechanical, chemical, or thermal damage to tissue stimulate nociceptive neurons
- These nociceptive ("pain sensing") neurons increase their discharge rate
- Discharge rate is in proportion to the logarithm of stimulus intensity
- High-threshold nociceptors respond only when stimulus intensity exceeds a threshold
- Tissue Destruction
- Activates nociceptive neurons directly
- Also activates inflammatory pathways
- Inflammation leads to release of many cytokines with nociceptive modifying (as well as inflammatory) activities
- Key neural function of inflammatory compounds is to amplify nociceptive signals
- Thus, inflammation and pain pathways are linked (see below)
- Nerve Fibers involved in Sensation
- Type A ß - light touch, hair movement (myelinated)
- Type A delta1 - mechanical force (myelinated)
- Type A delta2 - thermal, mechanical (± myelination)
- Type C - polymodal pain fibers (0.5-1.5µm axon diameter)
- Nociceptive Nerve Fibers
- Type C nerve fibers appear to be major carriers of nociceptive signals
- Type A delta2 nerve fibers detect heat/cold and other noxious stimuli
- These fibers carry nociceptive information from visceral and somatic sites
- Under conditions of C fiber damage, A delta2 fibers can transmit pain information [7]
- The information is carried to the dorsal horn of the spinal cord
- The dorsal horn neurons integrates incoming signals and adapts to them ("memory")
- Pain sensation and "memory" are critical elements in neuropathic pain (below)
- Dorsal horn neurons form spinal ascending pathways
- Ascending pathways then relay nociceptive information to various brain centers
- These include thalamic, limbic and cortical structures responsible for affective and sensory-discriminative responses
- Larger nerve fibers (Aß and A-alpha) responsible for proprioception, vibratory sensation, muscle-stretch reflexes and muscle strength may also be affected in pain [10]
- Neurotransmitters Mediating Pain
- Substance P (SP)
- Neuropeptide Y (NP-Y)
- ATP
- Neurokinin 1 (NK-1)
- Cholecystekinin (endogenous inhibitor of opioid receptors)
- Glutamate
- Bombesin
- Calcitonin Gene Related Peptide (CGRP)
- Adenosine
- Modulating effects by serotonin
- Neurotransmitters Inhibiting Pain
- Peripheral opiates
- Central opiates (endorphins) are main pain blockers
- Gamma-aminobutyric acid (GABA)
- Glycine
- Enkephalins
- Receptors Associated with Nociceptors
- Glutamate (NMDA and AMPA type) receptors
- NK-1 receptor
- Acetylcholine receptor
- Neuropeptide Y receptor
- PGE receptor
- Adenosine receptor
- GABA-A and GABA-B receptors
- Somatostatin receptor
- Adrenaline (epinephrine, ß-adrenergic) receptor
- Opioid receptors (mu, kappa, delta subtypes)
- CCK receptor
- Serotonin receptor
- Bradykinin receptor
- Histamine receptor
- Bombesin receptor
- SP (capsaicin) receptor
- Others
C. Neuropathic Pain [3]
- Neuropathic pain is chronic pain which persists after an acute insult which has resolved
- It comprises a group of persistent pain syndromes with no clear etiology
- For a specific insult which has resolved, only a small percentage of patients will develop neuropathic pain
- Currently there is no way to predict which patients will develop neuropathic pain
- Chronic pain is independently related to low self-rated health [11]
- Classification of Neuropathic Pain
- Currently classified on basis of insult which caused the insult to nervous system
- It appears that any type of trauma can induce long-term, "memory"-like pain responses
- Moreover, ischemic, metabolic, toxic, infectious or other tissue damage can lead to neuropathic patin syndromes
- Allodynia - pain evoked by a normally innocuous stimulus
- Hyperalgesia - enhanced pain evoked by a noxious stimulous
- Proposed Pathophysiology [3,4,5]
- May be caused by primary lesion in central or peripheral nerves
- Spinal neuron hyperexcitation may play a critical role in persistance of pain
- Spontaneous activity in C fibers thought to be responsible for burning pain
- In addition, C fiber activity may be responsible for spinal neuron hyperexcitation
- Stimulus independent activity in large myelinated type A fibers can cause paresthesias
- Increased expression of ion channels and receptors that initiate and mediate action potentials
- Tetrodotoxin insensitive sodium channels are likely involved in spontaneous activities
- Sympathetic nervous system may have some role in a few patients
- Reduction in GABA inhibitory neurotransmitters in dorsal horn has also been found
- NMDA type glutamate receptors in the CNS also play a key role
- Prodynorphin, an opioid neuropeptide, is expressed in spinal interneurons
- Prodynorphin stimulates kappa-opioid receptor signalling [8]
- Inflammation, driven by initial pain stimulus, can perpetuate neuronal firing
- Chemokines and their receptors may play an important role in maintaining neuronal firing [4]
- Stress response (hypothalmic-pituitary-adrenal) axis plays some role in pain sensation
- Symptoms
- Persistent or paroxysmal pain independent of a stimulus
- Pain may be shooting, lancinating or burning
- Stimulus evoked pain may also occur and includes hyperalgesia and allodynia
- Hyperalgesia is increased pain response to suprathreshold noxious stimulus
- Hyperalgesia is due to abnormal processing of nociceptive input (likely dorsal horn)
- Allodynia is sensation of pain elicted by non-noxious stimulus
- Allodynia may be caused by action of low threshold Aß fibers at CNS level or by reduction in the threhold of nociceptor terminals in the periphery
- Common Neuropathic Pain Conditions
- Trigeminal Neuralgia
- Reflex Sympathetic Dystrophy Syndrome
- Post-Phlebitic Syndrome
- Phantom-Limb Syndrome
- Diabetic neuropathy
- Current Therapy
- Largely inadequate
- Carbamazepine and gabapentin have reasonably good efficacy in trigeminal neuralgia
- Gabapentin (Neurontin®) has good efficacy in postherpetic neuralgia, diabetic neuropathy
- Combined gabapentin + morphine is superior to either for severe neuropathic pain [12]
- Opioids - usually necessary to adequately control pain but equivocal short term efficacy [13]
- Higher doses of opioids more effective on pain control but not sleep or activity levels compared with lower doses in chronic neuropathic pain [9]
- Other antiepileptics, particularly with sodium channel blocking activity
- Mexilitine - antiarrhythmic / analgesic with Na channel blocking activity
- Alpha adrenergic receptor blockers
- Calcium channel blockers have little activity
- Experimental Therapy
- Sodium Channel Blockers - specific for neuronal Na Channels
- NMDA Antagonists
- Neurokinin 1 Receptor blockers
- Neuronal nitric oxide synthase blockers / glycine site antagonists
- Protein kinase C gamma inhibitors
- Chemokine receptor blockers [4]
- Nerve growth factor
D. Visceral Pain [6]
- Characteristics
- Not evoked from all viscera (not from kidney, liver, lung parenchyma)
- Not always linked to visceral injury
- Diffuse and poorly loclaized
- Often referred to other locations
- Accompanied with motor and autonomic reflexes (nausea, vomiting, muscle tension)
- Mechanisms
- High threshold receptors and intensity coding receptors contribute to visceral pain
- Brief acute pain (such as acute colonic pain) likely triggered by activation of high threshold afferents
- Extended forms of noxious stimuli (such as ischemia) result in sensitization of high threshold receptors and stimujlate previously unresponsive silent nociceptors
- Once sensitized, these nociceptors will fire early in noxious stimulus process
- Organ inflammation (including that related to ischemia) augments these processes
- Afferent Neurons Innervating Somatic and Visceral Tissues
- Two distinct biochemical classes: peptide class (SP and CGRP) and non-peptide class
- These neurons are fine caliber unmyelinated (Type C) primary afferents
- Most visceral afferent fibers belong to the SP/CGRP class of neurons
- SP appears to play an important role in mediating visceral pain
- Spinal Pathways
- Three different pathways appear to carry visceral nociceptive information
- Dorsal column
- Spino(trigemino)-parabrachioamygdaloid
- Spinohypothalamic
- Repeated noxious stimulation of visceral afferents can induce excitability in the CNS
- Changes in both the spinal cord and brain have been found
- May play a role in autonomic and motor reflexes commonly found with visceral pain
- Hunched posture in appendicitis may be due to these changes
- Treatment
- Current treatment is symptomatic with little specificity for visceral pain pathways
- Opiates are the mainstay of therapy for severe visceral pain
- However, blocking substance P may be more specific and effective
- Serotonin receptors may reduce peripheral neural sensitization
- NMDA inhibitors may reduce central neural sensitization
E. Pain And Inflammation [1]
- Leukocytes and platelets may release locally active neurohormones causing pain
- Prostaglandin E
- Adenosine
- Bradykinin
- Histamine
- ATP
- Opioids
- Adenosine
- Glutamate
- Serotonin
- Lymphocytes also have opiate receptors which may down regulate inflammation
- May explain efficacy of glucocorticoids in some pain-related conditions
- Inflammatory diseases
- Neoplastic diseases
References
- Woolf CJ. 2004. Ann Intern Med. 140(6):441

- Loeser JD and Melzack R. 1999. Lancet. 353(9164):1607

- Woolf CJ and Mannion RJ. 1999. Lancet. 353(9168):1959

- White FA, Jung H, Miller RJ. 2007. Proc Natl Acad Sci USA. 104(51):20151

- Gottschalk A, Smith DS, Jobes DR, et al. 1998. JAMA. 279(14):1076

- Cervero F and Laird JMA. 1999. Lancet. 353(9170):2145

- Baron R. 2000. Lancet. 356(9232):785

- Vogt BA. 2002. NEJM. 347(5):362

- Rowbotham MC, Twilling L, Davies RS, et al. 2003. NEJM. 348(13):1223

- Mendell JR and Sahenk Z. 2003. NEJM. 348(13):1243

- Mantyselka PT, Turunen JHO, Ahonen RS, Kumpusalo EA. 2003. JAMA. 290(18):2435

- Gilron I, Bailey JM, Tu D, et al. 2005. NEJM. 352(13):1324

- Eisenberg E, McNicol ED, Carr DB. 2005. JAMA. 293(24):3043
